Latest Conference Articles

Patients who switched to insulin glargine 300 Units/mL were 57% less likely to experience hypoglycemia at 6-months.

Teens with T1D improved their A1C levels by frequent 2-way texting.

Severely obese American Indian children had a 12-times higher risk of developing T2D as normal-weight youth.

Boys who are overweight as children but normalize as young adults have the same risk of type 2 diabetes as men who were never overweight.

More than 3,000 original research presentations will be offered in a robust 5-day program.

A disease that affects the motor and cognitive system can be treated well by physical therapy and exercise, Daniel M. Corcos, PhD, said.

Daniel M. Corcos, PhD, discusses the value of routine balance intervention activities for Parkinson's disease patients at the 21st International Congress of Parkinson's Disease and Movement Disorders.

Aleksandar Videnovic, MD, associate professor at the Massachusetts General Hospital, discusses new patient monitoring opportunities and other methods of treatment for one of Parkinson's disease patients' most common symptoms.

BMS-986168 significantly reduces CSF free eTau.

A Phase II-B trial with early to moderate PD patients showed efficacy.

An Italian team presented its research on the topic at the 2017 International Congress of Parkinson’s Disease & Movement Disorders Conference.

Anthony Lang, MD, FRCPC, professor and director of the Division of Neurology at the University of Toronto, discusses the potentially comprehensive care of investigational disease modifying treatment PRX002,

The study gauged elderly Parkinson's patients over a 5-year span.

Psychosis and dementia are major risk factors for Parkinson's patients.

Laxman Bahroo, DO, explains how no treatment has shown more efficacy for Tardive Dyskinesia against placebo than valbenazine (Ingrezza), and how its approval changes the scope of the movement disorder.

An expert offers insights on levodopa-induced motor complications in Parkinson’s disease.

Norika Malhado-Chang, MD, assistant professor of Neurology at University of California at Davis, discusses how progress in Parkinson's disease and movement disorders is changing the scope of comprehensive care, addressing non-motor symptoms, and supplying tools for the next generation of neurology specialists.

A study has found an alternative motor treatment from levodopa.

The first step in successfully treating chorea is making the correct diagnosis.

Specific dystonia cases require specific treatments.

Researchers were able to pull 25,000 hours of monitoring data.

"We have some major changes in the way we treat Parkinson's."

Associations between race/ethnicity and lack of in healthcare access were found.

John Dirk Nieland, PhD, associate professor in the Department of Health Science and Technology at Aalborg University in Denmark, discusses his research team's connection between MS and lipid metabolism, the importance of condition-inflicted models, and the encompassing nature of treating MS.

At AAPA 2017 in Las Vegas, Jennifer Carlquist PA-C, ER, CAQ said that she believed clinicians are trained in medicine to think heart disease is "an old person's disease," so they don't have it on their radar for the young people (teen years through mid-30s).

The conclusion to our 2-part interview with a leading expert in neurocognitive disorders in the geriatric patient.

Leading expert on neurocognitive disorders explains their impact on the elderly patient in this interview.

Dr. Kiki Chang sits down with MD Magazine and talks about the latest data on lurasidone.

Clyde Markowitz, MD, discusses how ocrelizumab, the most recent FDA-approved multiple sclerosis (MS) treatment, doesn't need to have "blockbuster" results to progress the state of MS treatment.

Leading eating disorder expert concludes her in-depth interview with MD Magazine by talking about some new treatments in development for these life-altering disorders.